Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Heterologous prime-boost immunisation with RTS,S/AS02A and the poxvirus MVA-CS was evaluated in 18 healthy malaria-naïve subjects in Oxford. Both priming with RTS,S and boosting MVA-CS, and the reverse, were found to be safe and well tolerated. T cell responses as measured by IFN-gamma ex vivo ELISPOT were induced, but the responses were low to moderate in both groups, with heterologous boosting yielding only small increments in T cell immunogenicity and no increased antibody response. Protection against 3D7 Plasmodium falciparum sporozoite challenge 4 weeks after the final vaccination was equal for both regimens at 33% (95% C.I. 4.3-77.7%), with one subject remaining fully protected on rechallenge at 5 months.

Original publication

DOI

10.1016/j.vaccine.2005.12.041

Type

Journal article

Journal

Vaccine

Publication Date

05/04/2006

Volume

24

Pages

2850 - 2859

Keywords

Adolescent, Adult, Antibodies, Protozoan, Female, Humans, Immunization, Secondary, Interferon-gamma, Malaria, Malaria Vaccines, Male, Middle Aged, T-Lymphocytes, Vaccinia virus